文献速递泌尿生殖与妇科肿瘤放疗

中危局限前列腺癌永久粒子植入近距离放疗的前瞻性2期试验:疗效、毒性与生活质量

Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-10-12

这项前瞻性2期试验纳入300例未经治疗的局限中危前列腺癌患者,2006至2013年接受单纯前列腺近距离放疗(未联合激素治疗)。5年生化无失败率为97.3%,总生存率94.9%,晚期3级泌尿毒性和直肠毒性分别为4例和2例,无4/5级毒性,多数患者对治疗满意。

要点

  • 5年生化无失败率97.3%(95%CI 95.1-99.5),总生存率94.9%(95%CI 92.1-97.9)。
  • 晚期3级泌尿毒性4例、直肠毒性2例,无4级或5级毒性。
  • 治疗4年时91%至93%患者表示满意或非常满意。

核心结论

  • 单纯近距离放疗对部分局限中危前列腺癌患者安全有效,并可获得良好生活质量。

研究设计与样本

  • 前瞻性2期试验纳入300例既往未经治疗的前列腺癌患者,治疗时间为2006年至2013年。
  • 入选条件为≤cT2b(经磁共振成像排除T3)、Gleason评分6且前列腺特异性抗原(PSA)10-15 ng/mL,或Gleason评分7且PSA<10 ng/mL。
  • 患者接受前列腺近距离放疗,未联合激素治疗。

主要发现

  • 患者中位年龄64.9岁,Gleason评分6占3.7%,Gleason评分7(3+4)占78.7%,Gleason评分7(4+3)占17.7%。
  • 中位随访5.1年,5年时PSA中位值为0.01 ng/mL(范围0-6.0 ng/mL)。
  • 发生10例生化失败,5年生化无失败率为97.3%(95%CI 95.1-99.5)。
  • 16例患者死亡,其中仅1例死于前列腺癌,5年总生存率为94.9%(95%CI 92.1-97.9),5年生化无进展生存率为92.7%(95%CI 89.3-96.2)。
  • 4例发生晚期3级泌尿毒性,2例发生晚期3级直肠毒性,未观察到4级或5级毒性。

关键数值与推荐

  • 治疗4年时报告「中度或严重问题」的比例:泌尿7.4%(基线0.4%)、肠道2.9%(基线0.4%)、性功能29.7%(基线19.7%)。
  • 治疗后2年91%的患者表示满意或非常满意,治疗后4年为93%。

临床怎么用

  • 对于符合入选条件的局限中危前列腺癌患者,单纯永久粒子植入近距离放疗可作为有效治疗选择,且不联合激素治疗。
  • 需关注晚期泌尿、直肠毒性及性功能相关问题,治疗前应与患者沟通生活质量影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the efficacy, physician-reported toxicity, and patient-reported outcomes of men with intermediate-risk prostate cancer after brachytherapy in a prospective phase 2 trial. METHODS AND MATERIALS: This prospective phase 2 trial involved 300 patients with previously untreated prostate cancer treated from 2006 through 2013. Eligible patients had ≤cT2b (T3 excluded according to magnetic resonance imaging), Gleason score (GS) 6 with prostate-specific antigen (PSA) level 10-15 ng/mL, or GS 7 with PSA <10 ng/mL, and were treated with prostate brachytherapy (without hormonal therapy). RESULTS: Median patient age was 64.9 years; 3.7% had GS 6, 78.7% had GS 7 (3+4), and 17.7% had GS 7 (4+3). Median follow-up time was 5.1 years. Median PSA at 5 years was 0.01 ng/mL (range, 0-6.0 ng/mL). Ten biochemical failures occurred, for a 5-year freedom from biochemical failure rate of 97.3% (95% confidence interval [CI], 95.1-99.5), and 16 patients died, only 1 from prostate cancer, for 5-year rates of overall and biochemical progression-free survival of 94.9% (95% CI, 92.1-97.9) and 92.7% (95% CI, 89.3-96.2%). Four patients had late grade 3 genitourinary toxicity, and 2 patients had late grade 3 rectal toxicity; no grade 4 or 5 toxicity was observed. Rates of "moderate or big problems" at 4 years were 7.4% for urinary (vs 0.4% at baseline), 2.9% bowel (vs 0.4%), and 29.7% sexual function (vs 19.7%). Most men were "satisfied or extremely satisfied" (91% at 2 years after treatment and 93% at 4 years). CONCLUSIONS: Brachytherapy monotherapy is safe and effective and leads to good quality of life for some men with localized intermediate-risk prostate cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Frank SJ, Pugh TJ, Blanchard P, et al. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys. 2017. PMID: 29229325. doi:10.1016/j.ijrobp.2017.09.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。